logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11648311 B1

PDFFull Text
Date of Patent:
May. 16, 2023

Filed:

May. 12, 2020

Cancer treatments

Applicant:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Inventors:

Svetomir N. Markovic, Rochester, MN (US);

Wendy K. Nevala, Rochester, MN (US);

Assignee:

Mayo Foundation for Medical Education and Research, Rochester, MN (US);

Attorney:

Baker Botts L.L.P.

Primary Examiner:

Karen A Canella

Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/32 (2006.01); A61K 31/555 (2006.01); A61K 9/51 (2006.01); A61K 47/64 (2017.01); A61K 47/68 (2017.01); A61K 47/69 (2017.01); A61K 9/00 (2006.01); A61K 41/00 (2020.01); A61K 45/06 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); A61K 33/243 (2019.01); A61K 39/00 (2006.01); A61K 31/337 (2006.01); C07K 16/30 (2006.01); A61K 31/282 (2006.01); A61K 9/14 (2006.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 9/0019 (2013.01); A61K 9/14 (2013.01); A61K 9/51 (2013.01); A61K 9/5169 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/555 (2013.01); A61K 33/243 (2019.01); A61K 39/001104 (2018.08); A61K 39/395 (2013.01); A61K 41/0052 (2013.01); A61K 45/06 (2013.01); A61K 47/643 (2017.08); A61K 47/6801 (2017.08); A61K 47/6803 (2017.08); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6863 (2017.08); A61K 47/6865 (2017.08); A61K 47/6867 (2017.08); A61K 47/6929 (2017.08); A61K 47/6931 (2017.08); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/2893 (2013.01); C07K 16/3015 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/6056 (2013.01); B82Y 5/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

This invention relates to antibody-albumin nanoparticle complexes comprising albumin, an antibody with binding specificity for a cancer antigen (e.g. panitumumab), and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g. EGFR binding specificity), for the purpose of providing cancer (e.g. EGFR-related cancer) treatments in a subject in need thereof.

Find Patent Forward Citations

Markovic, Svetomir. (2023). Cancer treatments (U.S. Patent No. 11648311). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11648311

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…